- Home
- RYDE vs APM Comparison
RYDE vs APM Comparison
Compare RYDE & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- APM
- Stock Information
- Founded
- RYDE 2014
- APM 2010
- Country
- RYDE Singapore
- APM United Kingdom
- Employees
- RYDE N/A
- APM N/A
- Industry
- RYDE
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- APM Health Care
- Exchange
- RYDE NYSE
- APM Nasdaq
- Market Cap
- RYDE 7.0M
- APM 6.1M
- IPO Year
- RYDE 2024
- APM 2018
- Fundamental
- Price
- RYDE $0.21
- APM $1.07
- Analyst Decision
- RYDE
- APM
- Analyst Count
- RYDE 0
- APM 0
- Target Price
- RYDE N/A
- APM N/A
- AVG Volume (30 Days)
- RYDE 149.2K
- APM 85.4K
- Earning Date
- RYDE 05-02-2025
- APM 06-17-2025
- Dividend Yield
- RYDE N/A
- APM N/A
- EPS Growth
- RYDE N/A
- APM N/A
- EPS
- RYDE N/A
- APM N/A
- Revenue
- RYDE $6,557,978.00
- APM N/A
- Revenue This Year
- RYDE $21.13
- APM N/A
- Revenue Next Year
- RYDE $13.43
- APM N/A
- P/E Ratio
- RYDE N/A
- APM N/A
- Revenue Growth
- RYDE 3.27
- APM N/A
- 52 Week Low
- RYDE $0.18
- APM $0.46
- 52 Week High
- RYDE $22.49
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- APM 58.89
- Support Level
- RYDE N/A
- APM $0.83
- Resistance Level
- RYDE N/A
- APM $1.35
- Average True Range (ATR)
- RYDE 0.00
- APM 0.12
- MACD
- RYDE 0.00
- APM 0.02
- Stochastic Oscillator
- RYDE 0.00
- APM 46.97
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.